[20200210]IF11250_美国食品和药物管理局对大麻二酚(CBD)消费品的监管.pdf

上传人:任我行 文档编号:28901 上传时间:2022-06-24 发布时间:2020-02-10 格式:PDF 页数:3 大小:454.58KB
下载 相关 举报
[20200210]IF11250_美国食品和药物管理局对大麻二酚(CBD)消费品的监管.pdf_第1页
第1页 / 共3页
[20200210]IF11250_美国食品和药物管理局对大麻二酚(CBD)消费品的监管.pdf_第2页
第2页 / 共3页
[20200210]IF11250_美国食品和药物管理局对大麻二酚(CBD)消费品的监管.pdf_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

1、 https:/crsreports.congress.gov Updated February 10, 2020FDA Regulation of Cannabidiol (CBD) Consumer ProductsCannabidiol (CBD) is promoted as treatment for a range of conditions, including anxiety, pain, inflammation, and post-traumatic stress disorderdespite limited scientific evidence to substant

2、iate or disprove many of these claims. CBD is derived from the Cannabis sativa plant (commonly referred to as cannabis), which includes both marijuana and hemp. CBD and tetrahydrocannabinol (THC) are thought to be the most abundant cannabinoids in cannabis. CBD is considered to be nonpsychoactive an

3、d may be derived from either hemp or marijuana. THCa psychoactive compoundis found at high levels in marijuana and low levels in hemp. For additional information, see CRS Reports R46189 and R44742. Regulation of Cannabis: Overview Botanically, marijuana and hemp are from the same species of plant, C

4、annabis sativa, but from different varieties or cultivars. Marijuana and hemp have separate definitions in U.S. law and are subject to different statutory and regulatory requirements. Marijuana (as defined in statute) generally refers to the cultivated plant used as a psychotropic drug, either for m

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告